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Abstract Vitamin D has been suggested to have an effect on
erythropoiesis. We sought to evaluate the prevalence of
anemia in a population of individuals with vitamin D
deficiency compared with those with normal levels in a
population of a large integrated healthplan. A cross-sectional
analysis in the period 1 January 2004 through 31 December
2006 of subjects with documented concurrent levels of 25-
hydroxyvitamin D and hemoglobin were evaluated. Vitamin
D deficiency was defined as <30 ng/mL and anemia was
defined as a hemoglobin <11 g/dL. A total of 554 subjects
were included in the analysis. Anemia was present in 49% of
25-hydroxyvitamin D-deficient subjects compared with 36%
with normal 25-hydroxyvitamin D levels (p<0.01). Odds
ratio for anemia in subjects with 25-hydroxyvitamin D
deficiency using logistic regressions and controlling for age,
gender, and chronic kidney disease was 1.9 (95% CI 1.3–
2.7). 25-hydroxyvitamin D-deficient subjects had a lower
mean Hb (11.0 vs. 11.7; p=0.12 ) and a higher prevalence of
erythrocyte stimulating agent use (47% vs. 24%; p<0.05).
This study demonstrates an association of vitamin D
deficiency and a greater risk of anemia, lower mean
hemoglobin, and higher usage of erythrocyte-stimulating
agents. Future randomized studies are warranted to examine
whether vitamin D directly affects erythropoiesis.
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Background
New insights into the biologic functions of vitamin D have
led to interest in the clinical consequences of vitamin D
deficiency. In addition to its role in regulation of bone and
mineral metabolism, vitamin D has been implicated in a
wide array of biological actions including muscle strength-
ening [1, 2], cellular proliferation and differentiation [3–6],
immune system modulation [2, 3, 5, 7], inhibition of renin
synthesis [8], and insulin production [9].
The role of vitamin D in erythropoiesis has also been
suggested by severalclinicalobservations. In thehemodialysis
population, vitamin D repletion has been associated with dose
reductions in erythrocyte-stimulating agents (ESA) and in-
creased reticulocytosis [10, 11]. Vitamin D has been
demonstrated in bone marrow to affect marrow function
[12, 13]. Moreover, levels of 1,25 hydroxyvitamin D (the
active form of vitamin D) are several hundred-fold higher in
bone marrow compared with plasma [14]. Despite these
intriguing observations, there is overall paucity of clinical
studies investigating whether adequacy of vitamin D affects
blood hemoglobin (Hb) levels.
We undertookthisstudytoevaluatewhether anassociation
exists between 25-hydroxyvitamin D (D25) deficiency and
anemia in a population of individuals with and without
chronic kidney disease (CKD). Using the database of a large
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risk of anemia in a population of subjects with documented
D25 deficiency compared with those with normal D25 levels.
Methods
Study design
Kaiser Permanente Southern California (KPSC) is an
integrated healthplan comprising of 11 medical centers
and dozens of satellite clinics. KPSC covers the region
from Bakersfield to San Diego within a similar sun
exposure environment. These data were collected as part
of normal healthcare operations. All members have very
similar access to care for healthcare services, including
office visits, tests, and medications. Potentially eligible
subjects were those aged >17 years old with a minimum of
one D25 and one hemoglobin (Hb) level between January
1, 2004 and December 31, 2006 were identified using
internal lab codes. Quantitative determination of serum 25-
OHD was performed using the Nichols Advantage 25-OHD
Assay (Nichols Institute Diagnostics, San Clemente, CA).
Anemiawasdefinedas anHblevel <11g/dLforbothmen
and women. D25 deficiency was defined as a level <30 ng/
mL. All unique subjects with an Hb level drawn within
6 months of a D25 value were included in the analysis. This
included individuals with and without kidney disease but not
restricted to patients with kidney disease. If multiple Hb
values were drawn within the 6-month time period, the Hb
value closest in time to the D25 level was used. If multiple
D25 levels were drawn, the first D25 value with a concurrent
(within 6 months) hemoglobin value was selected for
analysis.
Data regarding age, gender, creatinine, estimated glo-
merular filtration rate (eGFR), calcium, phosphorus, serum
albumin, ESA use, iron saturation, and ferritin were
collected when available. Kidney function was assessed
by the abbreviated Modification of Diet in Renal Disease
study equation, which calculates eGFR based on serum
creatinine, age, sex, and black vs. non-black race [15, 16].
Conditions associated with inflammation/malnutrition can
affect levels of D25. Thus, patients with diabetes mellitus,
systemic lupus erythematosus, ulcerative colitis, and crohn’s
disease were identified based on ICD-9 coding. Patients with
iron deficiency anemia, folic acid deficiency, vitamin B12
deficiency, bacteremia and gastrointestinal bleed diagnosed
within 6 months of the cross-sectional time frame were
excluded from the study. Patients with a previous history of
sickle cell anemia, thalassemia, malignancies, myelodys-
plastic syndromes, and hemolytic anemia were also excluded.
The study protocol was approved by the institutional review
board of Kaiser Permanente Southern California.
Statistics
Univariate and multivariate logistic regression analyses
were used to calculate the odds ratio (OR) for anemia.
Confounding factors including age, eGFR <60 mL/min/
1.73 m
2, gender, black or non-black race, and ESA use were
included in the analysis. Secondary analyses compared
prevalence of anemia, absolute Hb levels, and prevalence
of ESA use in subjects with D25 deficiency compared with
those with normal D25 levels.
The chi-square and Fisher's exact tests were used to
compare the categorical variables including gender, per-
centage of African Americans in the study cohort, iron
saturation percentage, eGFR <60 mL/min/1.73 m2, ESA
use, percentage of hemoglobin <11.
Student's t test was used to assess for continuous
variables. Significance was evaluated using a two-sided
p value of less than 0.05. A multivariable logistic regression
examined the simultaneous influence of several variables
on the risk for anemia.
All statistics were performed by using SAS version 9.13.
(SAS Institute, Inc. Cary, North Carolina)
Results
Study subjects
A total of 554 subjects had concurrent Hb and D25 levels
within a 6-month period documented in the study period.
Of these subjects, 240 (43%) were D25 deficient and 314
(57%) had normal D25 levels. Patients with CKD with an
eGFR <60 mL/min/1.73 m
2 accounted for 65% of the study
population. Baseline characteristics and demographics are
described in Table 1.
Baseline characteristics of subjects according to D25
level are described in Table 2. Among subjects with D25
deficiency, 81% had an eGFR <60 mL/min/1.73 m
2 vs 53%
of subjects with D25 levels ≥30 ng/ml (p=<0.0001). Mean
serum ferritin level was 364 vs.189 ng/ml (p<0.01) and
mean total iron-binding capacity (TIBC) was 278 vs.
325 mcg/dl (p<0.01) for subjects with D25 levels <30
and ≥30 ng/ml, respectively. Forty seven percent of D25-
deficient subjects were on ESA vs. 23% of subjects with
normal D25 levels (p<0.01).
Primary analysis
Results of logistic regression analyses with and without
adjustment for covariates are described in Table 3.I n
subjects with D25 deficiency, the OR for anemia control-
ling for age, gender, ESA use, and eGFR <60 mL/min/
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2 was 1.86 (95% CI 1.29–2.68) compared with
subjects without D25 deficiency. Other variables including
age, gender, ESA use, and eGFR <60 mL/min/1.73 m
2
were not statistically significant in the multivariate regres-
sions analyses (Table 3).
Secondary analysis
The prevalence of anemia in the D25-deficient group was
48% (n=117) compared with 36% (n=112) in normal D25
group (Table 2). Of the 554 subjects, 228 (41%) had
moderate vitamin D25 deficiency (D25 11–29 ng/ml) and
12 (2%) had severe vitamin D deficiency (≤10 ng/ml)
totaling to 240 (43%). In subjects with moderate and severe
D25 deficiency, 109 (48%) and eight (67%) were anemic,
respectively.
In subjects not on ESA therapy, mean Hb levels were
11.2 g/dL in the D25-deficient group compared with 11.8 g/
dL in the normal D25 group (p<0.01). In terms of ESA use,
47% of D25-deficient subjects were on ESA therapy versus
24% in the group with normal D25 levels (p<0.01).
In individuals where albumin and diabetes mellitus data
were available, there were significant differences in mean
albumin and diabetes mellitus rates between D25-deficient
and normal individuals (albumin 3.1 vs 3.4, p<0.01; diabetes
mellitus 65% vs 43%, p<0.01). D25-deficient patients had
lower rates with normal albumin levels (≥4 g/dL) than D25
normal patients (50% vs 67%; p<0.01). In anemia patients,
albumin and D25 had a significant correlation (Pearson's
D25<30 D25≥30 p value
Number of individuals 240 314
Mean D25 level 20.9 (±5.8) 47.2 (±14.8)
Female (%) 61.3 67.8 0.11
Mean Age (years) 66.4 64.2 0.08
Blacks (%) 21.3 21.0 0.68
a
Ferritin (ng/mL) 364 189 0.01
Iron saturation (%) 28 24.8 0.06
TIBC (mcg/dL) 278 325 <0.01
eGFR<60 mL/min/1.73 m
2 (%) 80.8 53.2 <0.01
Mean albumin (±SD) 3.1 (±0.8) 3.4 (±0.7) <0.01
b
N=188 N=187
Diabetes mellitus (%) 65.4 43.0 <0.01
N=157 N=135
Sytemic lupus erythematosus (%) 3.8 1.3 0.06
c
N=9 N=4
Crohn's disease (%) 2.1 0.6 0.25
c
N=5 N=2
Ulcerative colitis (%) 1.3 0.3 0.32
c
N=3 N=1
ESA use (%)
d 47.1 23.6 <0.01
Hb<11 (%)
d 48.8 35.7 <0.01
Mean Hb
Total 11.0 11.7 0.12
Pt on ESA 10.9 11.3 <0.01
N=113 N=74
Pt not on ESA
d 11.2 11.8 <0.01
N=127 N=240
Table 2 Subject characteristics
by vitamin D status
N=554
aChi-square test
bStudent's t test
cFisher's exact test
dSecondary outcome data
Table 1 Subject population characteristics
Number of patients
Mean age (years) 65 554
Female (%) 65 360
Race
Black (%) 21 117
CKD (%; GFR<60 mL/min/
1.73 m
2)
65 361
Iron indices
Iron saturation 26% 393
Ferritin 289 ng/mL 376
Iron 67 mcg/dL 404
TIBC 302 mcg/dL 392
Percent on ESA 34 187
N=554
Ann Hematol (2010) 89:447–452 449correlation coefficients=0.21; p value <0.01). Such a
correlation did not exist for our non-anemia patients
(Pearson's correlation coefficients=0.12; p value=0.09).
Rates of systemic lupus erythematosus, ulcerative colitis,
and Crohn's disease were not significantly different between
out D25-deficient and D25 normal individuals.
Discussion
This study demonstrates a greater prevalence and risk of
anemia in individuals with D25 deficiency compared with
those with normal D25 levels. The percentage of subjects
with anemia and subjects on ESA therapy were higher in
the D25 deficiency group compared with those with normal
D25 levels. In addition, D25-deficient subjects also had a
lower mean Hb level compared with those with normal D25
levels. A multivariate logistic regression analysis control-
ling for gender, age, renal insufficiency, and ESA use
revealed an OR of 1.9 for anemia in subjects with D25
deficiency versus those with normal D25.
Subjects with D25 deficiency had higher serum iron
saturations, ferritins, and lower TIBC levels compared with
those with normal D25 levels. Thus, iron deficiency based
on laboratory studies could not account for the higher
proportion of anemia in subjects with low D25 levels.
Although iron adequacy may not be a factor of anemia, the
higher levels of ferritin and lower serum albumin does
suggest that malnutrition and inflammation may have been
more prevalent in D25-deficient individuals which intro-
duces a confounder for the association evaluated in this
study.
While our study found a correlation between D25
deficiency and anemia, a causal relationship cannot be
established. There may have been additional confounding
factors that played a role in reducing both erythropoiesis
and D25 stores. For example, patients with anemia may
have more illnesses and debility preventing them from
adequate sun exposure. Concurrent D25 and Hb levels were
drawn within 6 months of each other in this study, but D25
levels could have changed within 6 months of time and
might not reflect true concurrent levels. The etiology of
anemia was not evident for each individual, but common
obvious causes such as iron, B12, and folate deficiency
were excluded along with individuals with documented
secondary causes of anemia such as blood and marrow
disorders and anemia due to bleeding. Another possible
confounder is selection bias inherent in the observational
nature of the study.
Individuals who had their vitamin D levels drawn may
have been disproportionately represented by patients that
were seen by a certain specialty department and thus, not
reflect the general patient population. The high prevalence
of anemia itself reflects this bias. Anemia in of itself may
have predisposed patients to D25 deficiency as anemic
patients due to fatigue may have been less likely to go
outside and obtain adequate sun exposure. Lastly, we did
not separate anemia by gender as females generally have
lower Hb levels than males. However, anemia was defined
for this study as a level <11 g/dL which would be
considered clinically significant for both genders.
A high percentage of patients with CKD (65%) were
included in this study, but a significant portion without CKD
was also included. Chronic kidney disease can lower the
total number of 1,25-hydroxyviatmin D levels because the
kidney is the largest source for 1-alpha-hydroxylase in
the body. The 1-alpha-hydroxylase converts D25 into active
1,25-hydroxyvitamin D which ultimately regulates bone and
mineral health. The total systemic stores and levels of D25
however are and should not be directly affected by depressed
kidney function.
In the D25-deficient population, 20% had normal renal
function (Table 2). This is consistent with observational
data on the non-CKD population where D25 deficiency is
not uncommon and even highly prevalent in certain subsets
of the general population. For instance, the elderly,
postmenopausal women, and individuals in colder climates
have D25 deficiency rates exceeding 50% of the population
[17–19]. Observations on the general populations have
demonstrated prevalence rates around 15–25% [17, 20].
Individuals with propensity for decreased skin synthesis of
D25 or decreased gut absorption are at risk of D25
deficiency [4, 21].
Comorbidities such as inflammatory bowel disease and
other conditions associated with malnutrition can affect gut
absorption of D25. Thus, patients with diabetes mellitus,
systemic lupus erythematosus, ulcerative colitis, and
Crohn's disease were identified within D25 levels. Albumin
Dependent variable OR (95% CI) OR with adjustments for covariables
a (95% CI)
Vit D <30 vs ≥30 1.72 (1.22–2.42) 1.86 (1.29–2.69)
Gender (male vs female) 0.79 (0.55–1.13) 0.76 (0.53–1.09)
Age (<60 vs >60) 0.99 (0.63–1.57) 0.93 (0.58–1.50)
ESA use (yes vs no) 1.17 (0.82–1.67) 1.17 (0.79–1.76)
eGFR (<60 vs ≥60) 1.08 (0.71–1.63) 1.06 (0.70–1.63)
Table 3 Odds ratio for anemia
using logistic regression
analysis
aEach dependent variable is
simultaneously adjusted for the
other four covariables in the
column
450 Ann Hematol (2010) 89:447–452was evaluated as a surrogate for nutritional status, and the
significant difference present between the D25 normal and
D25-deficient group further suggests the confounding of
malnutrition in our study. Overall presence of systemic
lupus erythematosus, ulcerative colitis, and Crohn's disease
were rare in our study population and between D25-
deficient and D25 normal individuals.
This study evaluated clinically significant anemia based
on D25 levels in patients with and without CKD. Previous
studies have examined vitamin D deficiency and ESA
usage in patients with end-stage renal disease (ESRD). Saab
et al. [11] observed a reduction of epoetin alfa doses after
treatment of D25 deficiency with ergocalciferol in
hemodialysis-dependent patients, but anemia was not a
primary outcome of the study [22]. Aucella et al. [23]
demonstrated that administration of 1,25-hydroxyvitamin D
increased burst-forming unit erythroid proliferation in
patients with ESRD that was synergistic with epoetin alfa.
Our study is one of the first to investigate the association of
D25 and anemia that included subjects without CKD and/or
not on ESA.
Vitamin D appears to be associated with anemia; though
the mechanism is unknown. One possibility is that vitamin
D modulates the level of systemic cytokine production thus
reducing the inflammatory milieu that leads to anemia of
chronic disease. Both in vivo and in vitro studies have
demonstrated that calcitriol (1,25 hydroxyvitamin D)
reduces cytokine production [14]. Interestingly, in our
study, we found that patients with normal D25 levels had
lower ferritin levels than D25-deficient patients. This may
suggest a reduced state of chronic systemic inflammation in
those with normal D25 or an ineffective erythropoiesis in
D25-deficient patients.
Another possible mechanism is that vitamin D directly
stimulates erythroid precursors. Vitamin D receptors have
been discovered in numerous non-renal target tissues
including the bone marrow [12, 13]. Normalizing tissue
D25 levels may provide an adequate substrate for local tissue
production of 1,25 hydroxyvitamin D in hematopoietic
tissues via extra-renal tissue activity of the 1-alpha-
hydroxylase enzyme. Hematons (the buffy coat of bone
marrow containing erythroid precursors, fibroblast, endothe-
lial cells, lipid laden cells, and macrophages) have been
demonstrated to contain significantly higher concentrations
of D25 and 1,25-hydroxyvitamin D levels than bone marrow
plasma [23]. High local concentrations of 1,25 hydroxyvita-
min D in hematopoietic tissues may then directly activate
erythroid precursor cells in a paracrine fashion.
Based on our findings of an association between D25
deficiency and anemia, further investigation needs to be
conducted to evaluate whether there is a direct causal
effect of D25 deficiency on anemia. If vitamin D does
improve erythropoiesis then correction of a D25-deficient
state may lead to improvement in anemia in patients with
and without CKD.
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